WeissR, DziuraJ, BurgertTS, et al.Obesity and the metabolic syndrome in children and adolescents. N Engl J Med, 2004; 350:2362–2374.
2.
KumarS, KellyAS. Review of childhood obesity: from epidemiology, etiology, and comorbidities to clinical assessment and treatment. Mayo Clin Proc, 2017; 92:251–265.
3.
SkinnerAC, PerrinEM, MossLA, et al.Cardiometabolic risks and severity of obesity in children and young adults. N Engl J Med, 2015; 373:1307–1317.
4.
MaggeSN, GoodmanE, ArmstrongSC, et al.The metabolic syndrome in children and adolescents: Shifting the focus to cardiometabolic risk factor clustering. Pediatrics, 2017; 140:e20171603.
5.
HuangTT, SunSS, DanielsSR. Understanding the nature of metabolic syndrome components in children and what they can and cannot do to predict adult disease. J Pediatr, 2009; 155:e13–14.
6.
CaprioS, PerryR, KursaweR. Adolescent obesity and insulin resistance: Roles of ectopic fat accumulation and adipose inflammation. Gastroenterology, 2017; 152:1638–1646.
BalagopalPB, de FerrantiSD, CookS, et al.Nontraditional risk factors and biomarkers for cardiovascular disease: Mechanistic, research, and clinical considerations for youth: A scientific statement from the American Heart Association. Circulation, 2011; 123:2749–2769.
9.
YangRZ, LeeMJ, HuH, et al.Identification of omentin as a novel depot-specific adipokine in human adipose tissue: Possible role in modulating insulin action. Am J Physiol Endocrinol Metab, 2006; 290:E1253–1261.
10.
HidaK, WadaJ, ZhangH, et al.Identification of genes specifically expressed in the accumulated visceral adipose tissue of OLETF rats. J Lipid Res, 2000; 41:1615–1622.
11.
HidaK, WadaJ, EguchiJ, et al.Visceral adipose tissue-derived serine protease inhibitor: A unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A, 2005; 102:10610–10615.
12.
LiuS, DongY, WangT, et al.Vaspin inhibited proinflammatory cytokine induced activation of nuclear factor-kappa B and its downstream molecules in human endothelial EA.hy926 cells. Diabetes Res Clin Pract, 2014; 103:482–488.
13.
de Souza BatistaCM, YangRZ, LeeMJ, et al.Omentin plasma levels and gene expression are decreased in obesity. Diabetes, 2007; 56:1655–1661.
14.
Moreno-NavarreteJM, OrtegaF, CastroA, et al.Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity (Silver Spring), 2011; 19:1552–1559.
15.
PanHY, GuoL, LiQ. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract, 2010; 88:29–33.
16.
BuyukinanM, AtarM, CanU, et al.The association between serum vaspin and omentin-1 levels in obese children with metabolic syndrome. Metab Syndr Relat Disord, 2018; 16:76–81.
17.
FordES, AjaniUA, MokdadAH, et al.The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. Diabetes Care, 2005; 28:878–881.
18.
RidkerPM, EverettBM, ThurenT, et al.Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med, 2017; 377:1119–1131.
19.
SuleymanogluS, TascilarE, PirgonO, et al.Vaspin and its correlation with insulin sensitivity indices in obese children. Diabetes Res Clin Pract, 2009; 84:325–328.
20.
TanBK, AdyaR, FarhatullahS, et al.Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: Ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes, 2008; 57:801–808.
21.
Moreno-NavarreteJM, CatalanV, OrtegaF, et al.Circulating omentin concentration increases after weight loss. Nutr Metab (Lond), 2010; 7:27.
22.
ZhangM, TanX, YinC, et al.Serum levels of omentin-1 are increased after weight loss and are particularly associated with increases in obese children with metabolic syndrome. Acta Paediatr, 2017; 106:1851–1856.
23.
XuT, ZuoP, CaoL, et al.Omentin-1 is associated with carotid plaque instability among ischemic stroke patients. J Atheroscler Thromb, 2017. [Epub ahead of print]; DOI: 10.5551/jat.42135.
